Maternal embryonic leucine zipper kinase is stabilized in mitosis by phosphorylation and is partially degraded upon mitotic exit
- PMID: 20420823
- DOI: 10.1016/j.yexcr.2010.04.019
Maternal embryonic leucine zipper kinase is stabilized in mitosis by phosphorylation and is partially degraded upon mitotic exit
Abstract
MELK (maternal embryonic leucine zipper kinase) is a cell cycle dependent protein kinase involved in diverse cell processes including cell proliferation, apoptosis, cell cycle and mRNA processing. Noticeably, MELK expression is increased in cancerous tissues, upon cell transformation and in mitotically-blocked cells. The question of how MELK protein level is controlled is therefore important. Here, we show that MELK protein is restricted to proliferating cells derived from either cancer or normal tissues and that MELK protein level is severely decreased concomitantly with other cell cycle proteins in cells which exit the cell cycle. Moreover, we demonstrate in human HeLa cells and Xenopus embryos that approximately half of MELK protein is degraded upon mitotic exit whereas another half remains stable during interphase. We show that the stability of MELK protein in M-phase is dependent on its phosphorylation state.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.Breast Cancer Res. 2007;9(1):R17. doi: 10.1186/bcr1650. Breast Cancer Res. 2007. PMID: 17280616 Free PMC article.
-
Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers.Cancer Res. 2005 Nov 1;65(21):9751-61. doi: 10.1158/0008-5472.CAN-04-4531. Cancer Res. 2005. PMID: 16266996
-
MAPK inactivation is required for the G2 to M-phase transition of the first mitotic cell cycle.EMBO J. 1997 Nov 3;16(21):6407-13. doi: 10.1093/emboj/16.21.6407. EMBO J. 1997. PMID: 9351823 Free PMC article.
-
Maternal embryonic leucine zipper kinase (MELK): a novel regulator in cell cycle control, embryonic development, and cancer.Int J Mol Sci. 2013 Oct 31;14(11):21551-60. doi: 10.3390/ijms141121551. Int J Mol Sci. 2013. PMID: 24185907 Free PMC article. Review.
-
Enigmatic MELK: The controversy surrounding its complex role in cancer.J Biol Chem. 2020 Jun 12;295(24):8195-8203. doi: 10.1074/jbc.REV120.013433. Epub 2020 Apr 29. J Biol Chem. 2020. PMID: 32350113 Free PMC article. Review.
Cited by
-
MELK expression in breast cancer is associated with infiltration of immune cell and pathological compete response (pCR) after neoadjuvant chemotherapy.Am J Cancer Res. 2021 Sep 15;11(9):4421-4437. eCollection 2021. Am J Cancer Res. 2021. PMID: 34659896 Free PMC article.
-
Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.Oncotarget. 2016 Mar 22;7(12):13621-33. doi: 10.18632/oncotarget.7297. Oncotarget. 2016. PMID: 26871945 Free PMC article.
-
Transcriptomic analysis to elucidate the molecular mechanisms that underlie feed efficiency in meat-type chickens.Mol Genet Genomics. 2015 Oct;290(5):1673-82. doi: 10.1007/s00438-015-1025-7. Epub 2015 Mar 18. Mol Genet Genomics. 2015. PMID: 25782841
-
CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials.Elife. 2017 Mar 24;6:e24179. doi: 10.7554/eLife.24179. Elife. 2017. PMID: 28337968 Free PMC article.
-
A Novel Tetramethylpyrazine Chalcone Hybrid- HCTMPPK, as a Potential Anti-Lung Cancer Agent by Downregulating MELK.Drug Des Devel Ther. 2024 May 7;18:1531-1546. doi: 10.2147/DDDT.S449139. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38737331 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
